In a pilot study using a peptide QRHKPRE specific for EGFR labeled with Cy5 or KSPNPRF specific for ErbB2 labeled with IRDye800 for 22 BE patients, 92% of neoplastic lesions could be correctly diagnosed with a high T/B ratio with 11% false positives. This evidence concerns the gene ERBB2 and Barrett esophagus.